| Michael
Zalutsky, Pathology
Our laboratory is involved in the development of endoradiotherapeutic
agents for the treatment of cancer. Ongoing projects include
genetically engineered antibody fragments reactive with
the mutant epidermal growth factor receptor variant III
(EFFRvIII) and tenascin, labeled compounds binding to
the NE transporter, thymidine uptake analogues, and radiohalogenation
strategies to render molecules resistant to deiodinase
and protease mediated degradation. Aspects of this work
of potential interest to students include radiosynthesis,
cell processing of labeled templates and microdosimetric
studies on a cellular and subcellular level.
|
